COMP <GO>
SPRO vs UNH // ALTMAN Z-SCORE & DEBT/EQUITY
Spero Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: SPRO 6
— UNH 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: UNH
LAST: $1.06 (-4.50%) • MKT CAP: $64.6M
balance-sheet
0.20
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
balance-sheet
3.12
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPRO VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPRO | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.60% | 11.47% | +15.13 | SPRO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.1x | 16.4x | -11.35 | SPRO | /valuation <GO> |
| Free Cash Flow Yield | -19.53% | 6.48% | -26.01 | UNH | /fcf-yield <GO> |
| Operating Margin | 50.20% | 4.82% | +45.38 | SPRO | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 3.14% | +64.86 | SPRO | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.46% | +173.54 | SPRO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.20 | 3.12 | -2.92 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.2 | 59.2 | -18.01 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.3x | 17.7x | -11.44 | SPRO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $64.6M | $368.83B | -$368.77B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPRO REV | UNH REV | SPRO GROSS % | UNH GROSS % | SPRO FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.6M | $447.57B | — | 88.7% | -$12.6M | $16.07B |
| FY 2024 | $371.0K | $400.28B | — | 88.3% | -$23.4M | $20.70B |
| FY 2023 | $933.0K | $371.62B | — | 89.6% | -$33.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPRO // BETA —
UNH // BETA 0.33